Viz.ai Named Among Forbes Most Promising AI Companies in America

SAN FRANCISCO & TEL AVIV, Israel--(BUSINESS WIRE)--#AI--Viz.ai is proud to be recognized in the inaugural Forbes AI list as one of America’s 50 Most Promising Artificial Intelligence Companies. Viz.ai uses Artificial Intelligence (AI) to synchronize stroke care, thereby reducing time to treatment and expanding patient access to life-saving care.


The Forbes AI list highlights the most promising private companies that are applying artificial intelligence to solve problems in innovative ways. As the emerging leader in applied Artificial Intelligence for healthcare, Viz.ai focuses on ensuring the right patient sees the right doctor at the right time. “Artificial Intelligence can have a real impact on patient care by enabling efficient health systems that deliver better patient outcomes,” said neurosurgeon and CEO Dr. Chris Mansi.

“Viz.ai is the future of how healthcare needs to be implemented. I am made aware of potential strokes within minutes of the patient receiving their scan and can coordinate care even if the patient is a hundred miles away. I am excited to see how this can be applied to even more disease states,” said Dr. Don Frei, former president of the Society of Neurointerventional Surgery and interventional neuroradiologist at HCA, one of the largest health systems in the USA.

About Viz.ai:

Viz.ai is the leader in applied artificial intelligence in healthcare. Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about suspected stroke patients straight to a specialist who can intervene and treat.

In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis.

Viz.ai is located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures and Innovation Endeavors.


Contacts

Christy Maginn
Maginn Consulting LLC for Viz.ai
(703) 297-7194
christymmaginn@msn.com